温肾强脊方联合不同剂量阿托伐他汀治疗强直性脊柱炎合并颈动脉粥样硬化患者的临床观察

温肾强脊方联合不同剂量阿托伐他汀治疗强直性脊柱炎合并颈动脉粥样硬化患者的临床观察

张征,张家寅,周程,常显,刘蕊蕊,张天助,律景展,王涛

河北大学附属医院,河北大学附属医院,河北大学附属医院,河北大学附属医院,河北大学医学院,河北大学医学院,河北大学医学院,河北大学附属医院

收稿日期:2018-11-22 修回日期:2018-11-22 出版日期:2018-12-25
基金资助:
河北省保定市科学技术研究与发展指导计划资助项目（项目编号：17ZF271；项目名称：温肾强脊方联合美洛昔康治疗强直性脊柱炎的临床观察及对瘦素、IL-6、IL-17、IL-23的影响）；河北大学2018级大学生创新创业训练计划项目（项目编号：2018198；项目名称：温肾强脊方联合美洛昔康治疗强直性脊柱炎的临床观察及对瘦素、IL-17、IL-23的影响）

Clinical Observation of Wenshen Qiangji Decoction Combined with Different Doses of Atorvastatin in the Treatment of Ankylosing Spondylitis with Carotid Atherosclerosis

ZHANG Zheng,ZHANG Jiayin,ZHOU Cheng,CHANG Xian,LIU Ruirui,ZHANG Tianzhu,LV Jingzhan and WANG Tao

Affiliated Hospital of Hebei University,Affiliated Hospital of Hebei University,Affiliated Hospital of Hebei University,Affiliated Hospital of Hebei University,Hebei University,Hebei University,Hebei University,Affiliated Hospital of Hebei University

Received:2018-11-22 Revised:2018-11-22 Online:2018-12-25

摘要/Abstract

摘要： 目的：评价温肾强脊方联合不同剂量阿托伐他汀（atorvastatin）治疗强直性脊柱炎（ankylosing spondylitis，AS)合并颈动脉粥样硬化患者的疗效，并观察本联合方案对血清瘦素(LEP)、肿瘤坏死因子-α（TNF-α）、血沉(ESR)、C反应蛋白（CRP）的影响。方法：选取我院60例AS合并颈动脉粥样硬化患者作为研究对象，随机分为治疗组及对照组，每组各30例。治疗组给予口服温肾强脊方联合阿托伐他汀40 mg·d-1，疗程90 d；对照组口服温肾强脊方联合阿托伐他汀20 mg·d-1，疗程90 d。观察患者 LEP、TNF-α、ESR、CRP水平的变化。结果：治疗后两组患者LEP、TNF-α、ESR、CRP水平均低于治疗前（P＜0.05）；与对照组相比，治疗组患者LEP、TNF-α、CRP水平均较低，差异均有统计学意义（P＜0.05）。结论：阿托伐他汀联合温肾强脊方可降低AS患者LEP、TNF-α、ESR、CRP水平，加倍剂量阿托伐他汀更有助于改善患者体内的炎症状态，对降低LEP、TNF-α、CRP水平作用更强。

Abstract: Objective：To evaluate the clinical effects of wenshen qiangji decoction combined with different doses of atorvastatin in the treatment of ankylosing spondylitis (AS) with carotid atherosclerosis， and to observe the effects on LEP， TNF-α，ESR and CRP of this combination therapy.Methods： 60 cases of patients with AS combined with carotid atherosclerosis were randomly divided into the treatment group（n=30） and the control group（n=30）. Patients in the treatment group were treated with wenshen qiangji decoction combined with atorvastatin 40 mg·d-1， and those in the control group were treated with wenshen qiangji decoction combined with atorvastatin 20 mg·d-1. All of the patients were treated for 90 d. The changes of LEP， TNF-α， ESR and CRP levels were observed after the treatment. Results： After the treatment， levels of LEP， TNF-α， ESR，and CRP in the two groups were lower than those before the treatment（P＜0.05）. Compared with the control group，the treatment group had lower LEP， TNF-α and CRP levels， and the differences were statistically significant (P<0.05). Conclusion： Wenshen qiangji decoction combined with atorvastatin can reduce the levels of LEP， TNF-α， ESR and CRP in patients with ASDoubled doses of atorvastatin can improve the inflammatory state in the patients and has a supplementary effect on reducing the levels of LEP， TNF-α and CRP.

张征,张家寅,周程,常显,刘蕊蕊,张天助,律景展,王涛. 温肾强脊方联合不同剂量阿托伐他汀治疗强直性脊柱炎合并颈动脉粥样硬化患者的临床观察[J]. .

ZHANG Zheng,ZHANG Jiayin,ZHOU Cheng,CHANG Xian,LIU Ruirui,ZHANG Tianzhu,LV Jingzhan and WANG Tao. Clinical Observation of Wenshen Qiangji Decoction Combined with Different Doses of Atorvastatin in the Treatment of Ankylosing Spondylitis with Carotid Atherosclerosis[J]. .

参考文献

[1]常文静,蔡辉．类风湿关节炎早发动脉粥样硬化机制的研究进展[J]．中国免疫学杂志,2015；3(1)：426~428
[2] 谢宇杰．活血通脉片治疗类风湿关节炎伴发动脉粥样硬化临床观察[J]．中成药,2012；34(5)：795~798
[3] Sieper J,Rudwaleit W,Baraliakos X,et al．The Assessment of Spondyloarthritis international Society(ASAS)handbook：a guide assess to spondyloarthritis[J]．Ann Rheum Dis,2009,68：ii1~ii44．
[4] Anderson J J,Baron G,Vanderheijde D,et al． Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis[J]．Arthritis ＆ Rheumatism,2010,44(8)：1876~1886
[5] 中华中医药学会中医内科常见病诊疗指南[M]．北京：中国中医药出版社,2008
[6] Chou CH,Lin MC,Peng CL,et a1．A nationwide population- based retrospective cohort study：increased risk of acute coronary syndrome in patients with ankylosing spondylitis[J]．Seand J Rheumatol,2014,43(2)：132~136
[7] engtsson K,Forsblad-d’Elia H,Lie E,et a1．Are ankylosing spondylitis,psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events？A prospective nationwide population-based cohort study[J]．Arthritis Res Ther,2017,19(1)：102
[8] Braun J,Sieper J．Ankylosing spondylitis[J]．Lancet,2007, 369(9570)：1379-1390
[9] Zhang x,Liu R,Wang J,et a1．Risk of premature eerebrovascular disease in patients with ankylosing spondylitis[J]．Acta Reumatol Port,2016,41(4)：322~327
[10] Karabag T,Akpinar I,Okten RS,et a1．Severe main coronary artery disease in a young woman with ankylosing spondylitis[J]．Intern Med,2012,51(18)：2635~2637
[11] 杨春花,黄烽．强直性脊柱炎免疫遗传学和发病机制研究进展[J]．现代免疫学,2007；27(4)：265~269
[12] 朱超,韩星海,陈琦．瘦素在强直性脊柱炎发病机制中的作用[J]．医学信息,2009； 22(6)：1072~1074
[13] 赵佳,张朝明,熊大迁．内脂素与冠心病的关系研究进展[J]．现代临床医学,2014；40(1)：5~8
[14]张莉芸,黄烽．生物制剂治疗强制性脊柱炎研究进展．中华风湿病学杂志,2005；9(2)：112~115
[15] Valgimigli M,Merli E,Malagutti P, et al．Hydroxyl radical generation, levels of tumor necrosis facto-alpha,and progression to heart failure after acute myocardial infarction[J]． J Am Coll Cardiol,2004,43(11)：2000~2008
[16] Jovinge S ,Hultgårdh-Nilsson A ,Regnström J, et al． T Tumor necrosis factor-alpha activates smooth muscle cell migration in culture and is expressed in the balloon-injured rat aorta[J]．Arterioscler Thromb Vasc Biol,1997,17(3)：490~497
[17] 余盛龙,郭惠庄,张稳柱.氨氯地平阿托伐他汀钙片治疗高血压、冠心病合并颈动脉粥样硬化患者的疗效[J]．中国老年学杂志,2016；36(4)：823~825.
[18] ChenY Y ,Hsu MJ,Hsieh CY , et al．Andrographolide inhibits nuclear factor-Κb activation through JNK-Akt-p65 signaling cascade in tumor necrosis factor-α-stimulated vascular smooth muscle cells[J]．Scientific World Journal, 2014,2014：130381
[19] van Kuilenburg J,Lappegård KT,Sexton J,et al. Persisting thrombin activity in elderly patients with atrial fibrillation on oral anticoagulation is decreased by anti-inflammatory therapy with intensive cholesterol-lowering treatment[J]．J Clin Lipidol,2011,5(4)：273~280.
[20]朱中生,王海燕,王登峰,等．瑞舒伐他汀对载脂蛋白E基因缺陷小鼠动脉粥样硬化及LOX-1、NF-κB p65表达的影响[J]．解放军医学杂志,2014；39(12)：946．
[21] 李悦妍,关玉庆,苗伟,等．阿托伐他汀对动脉粥样硬化模型兔toll样受体4及其下游信号表达的影响[J]．山东大学学报：医学版,2014；52(26)：1
[22] Buraczynska K,Kurzepa J,Ksiazek A,et al. Matrix Metalloproteinase-9(MMP-9) Gene PolymoIphism in Stroke Patients[J]．Neuromolecular,Med,2015,17(4)：385．

快速检索引用检索图表检索高级检索